Clinical data | |
---|---|
Other names | Aureolic acid; Mithracin; Antibiotic LA 7017; Mithramycin A; Mitramycin; Plicatomycin |
AHFS/ Drugs.com | Micromedex Detailed Consumer Information |
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.162.065 |
Chemical and physical data | |
Formula | C52H76O24 |
Molar mass | 1085.156 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(what is this?) (verify) |
Plicamycin ( INN, also known as mithramycin; trade name Mithracin) is an antineoplastic antibiotic produced by Streptomyces plicatus. It is an RNA synthesis inhibitor. [1] The manufacturer discontinued production in 2000. Several different structures are currently reported in different places all with the same chromomycin core, but with different stereochemistry in the glycoside chain, a 1999 study has re-investigated the compound and proposed a revised structure. [2]
Plicamycin has been used in the treatment of testicular cancer, [3] [4] Paget's disease of bone, [5] [6] and, rarely, the management of hypercalcemia.
Plicamycin has been tested in chronic myeloid leukemia. [7]
Plicamycin is currently used in multiple areas of research, including cancer cell apoptosis [8] and as a metastasis inhibitor. [9]
One elucidated pathway shows it interacts by cross-binding chromatin GC-rich promoter motifs, thereby inhibiting gene transcription. [10]
Clinical data | |
---|---|
Other names | Aureolic acid; Mithracin; Antibiotic LA 7017; Mithramycin A; Mitramycin; Plicatomycin |
AHFS/ Drugs.com | Micromedex Detailed Consumer Information |
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.162.065 |
Chemical and physical data | |
Formula | C52H76O24 |
Molar mass | 1085.156 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(what is this?) (verify) |
Plicamycin ( INN, also known as mithramycin; trade name Mithracin) is an antineoplastic antibiotic produced by Streptomyces plicatus. It is an RNA synthesis inhibitor. [1] The manufacturer discontinued production in 2000. Several different structures are currently reported in different places all with the same chromomycin core, but with different stereochemistry in the glycoside chain, a 1999 study has re-investigated the compound and proposed a revised structure. [2]
Plicamycin has been used in the treatment of testicular cancer, [3] [4] Paget's disease of bone, [5] [6] and, rarely, the management of hypercalcemia.
Plicamycin has been tested in chronic myeloid leukemia. [7]
Plicamycin is currently used in multiple areas of research, including cancer cell apoptosis [8] and as a metastasis inhibitor. [9]
One elucidated pathway shows it interacts by cross-binding chromatin GC-rich promoter motifs, thereby inhibiting gene transcription. [10]